Dec 23, 2013 7:00am EST Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
Dec 19, 2013 7:00am EST Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
Nov 20, 2013 7:00am EST Can-Fite BioPharma Generates Partnership Interest at Therapeutic Area Partnerships Conference in Boston
Nov 05, 2013 1:08pm EST U.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure
